" " Pfizer, Tempus collaborate on cancer drug development – Wellness for Life " "
Wellness for Life
Advertisement
  • Home
  • News
  • Family Wellness
  • Health and Wellbeing
  • Mental Wellness
  • Contact us
No Result
View All Result
  • Home
  • News
  • Family Wellness
  • Health and Wellbeing
  • Mental Wellness
  • Contact us
No Result
View All Result
Wellness for Life
No Result
View All Result
Home News

Pfizer, Tempus collaborate on cancer drug development

admin by admin
March 2, 2023
in News



Multinational pharmaceutical and biotech company Pfizer and AI-powered data company Tempus announced a multi-year strategic alliance to utilize AI and machine learning to inform drug discovery and development in oncology. 

Pfizer will leverage Tempus’ library of de-identified data to accelerate therapeutic development in oncology. It will also use Tempus’ AI-driven companion diagnostic offerings and clinical trial matching program to support therapeutic research and development.

“Pfizer shares our commitment to bringing novel treatments to patients faster, and we look forward to working together to usher in the next generation of oncology therapeutics,” Eric Lefkofsky, founder and CEO of Tempus, said in a statement. “This is the third strategic collaboration Tempus has established with a global pharmaceutical leader in the last year, as we believe that combining our technological capabilities with pharma’s deep R&D expertise will get us much closer in realizing the full potential of precision medicine.”

THE LARGER TREND

Tempus is no stranger to partnering with pharma giants for oncology care. 

Last year, the company announced a three-year agreement with British multinational pharmaceutical and biotech company GSK, which included a $70 million initial payment to accelerate drug discovery in oncology, identify drug targets, improve its clinical trial design and speed up trial enrollment. 

The Chicago-based company also announced a collaboration with American pharma company Eli Lilly to broaden access to genomic testing for patients with advanced/metastatic non-small cell lung cancer. 

In 2021, Tempus announced a strategic collaboration with British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca to advance drug discovery and development in oncology. 

Last year, the company announced it scored $275 million in funding through a combination of debt financing and equity from existing investors, bringing its total raise to $1.3 billion. 

Other players utilizing AI for drug discovery in oncology include AI-enabled pathology company PathAI and tech company Exscientia.



Source link

Previous Post

Misunderstanding in Marriage | Jim Daly

Next Post

Finding financial support following a cancer diagnosis

Next Post

Finding financial support following a cancer diagnosis

Recommended

This IV Treatment for Tumors Shows Promise

March 20, 2023

Depression and Anxiety Increase in Teens Who Vape Nicotine and THC

March 4, 2023

Don't miss it

Family Wellness

Insomnia, Sleep Apnea Rise in Women With MS

March 28, 2023
Health and Wellbeing

Neutrogena’s Mineral UV Tint Is Kerry Washington’s Fave

March 28, 2023
Health and Wellbeing

Classic Breakfast Strata – Fit Foodie Finds

March 27, 2023
Health and Wellbeing

Relieving Arthritis in Seniors with Sauna Bath, Lifestyle and Health

March 27, 2023
News

Effect of Mental Health During COVID-19 Pandemic

March 27, 2023
News

Q&A: Improving the patient experience without stressing providers

March 27, 2023

© 2022 Wellness For Life News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Family Wellness
  • Health and Wellbeing
  • Mental Wellness
  • Contact us

Newsletter Sign Up

Loading

No Result
View All Result
  • Home
  • News
  • Family Wellness
  • Health and Wellbeing
  • Mental Wellness
  • Contact us

© 2022 Wellness For Life News Hubb All rights reserved.